Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Selective estrogen receptor degrader
DRUG CLASS:
Selective estrogen receptor degrader
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
fulvestrant (57)
elacestrant (9)
SAR439859 (9)
imlunestrant (7)
AZD9833 (7)
OP-1250 (7)
SCR-6852 (4)
RG6171 (4)
ZN-c5 (3)
AZD9496 (2)
GDC-0927 (2)
G1T48 (2)
LX-039 (1)
SCR6106 (1)
D-0502 (1)
AND019 (0)
DZD3969 (0)
LSZ102 (0)
SHR9549 (0)
GDC-0810 (0)
EGL-5385-C-1701 (0)
fulvestrant (57)
elacestrant (9)
SAR439859 (9)
imlunestrant (7)
AZD9833 (7)
OP-1250 (7)
SCR-6852 (4)
RG6171 (4)
ZN-c5 (3)
AZD9496 (2)
GDC-0927 (2)
G1T48 (2)
LX-039 (1)
SCR6106 (1)
D-0502 (1)
AND019 (0)
DZD3969 (0)
LSZ102 (0)
SHR9549 (0)
GDC-0810 (0)
EGL-5385-C-1701 (0)
›
Associations
(117)
News
Trials
VERI cancer hierarchy
Reset Filters
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
HR positive
Hormone Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
elacestrant
Sensitive: A1 - Approval
elacestrant
Sensitive
:
A1
elacestrant
Sensitive: A1 - Approval
elacestrant
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
No biomarker
Sarcoma
No biomarker
Sarcoma
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant + anastrozole
Sensitive: A2 - Guideline
fulvestrant + anastrozole
Sensitive
:
A2
fulvestrant + anastrozole
Sensitive: A2 - Guideline
fulvestrant + anastrozole
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant + letrozole
Sensitive: A2 - Guideline
fulvestrant + letrozole
Sensitive
:
A2
fulvestrant + letrozole
Sensitive: A2 - Guideline
fulvestrant + letrozole
Sensitive
:
A2
HR positive + HER-2 negative
Male Breast Cancer
HR positive + HER-2 negative
Male Breast Cancer
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.